Clinical Trial Update: Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPV [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the immunogenicity and safety of the primary dose of bOPV Bio Farma given simultaneously with Pentabio and IPV in healthy participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poliomyelitis

Drugs mentioned

• IPV (Inactivated poliovirus vaccine)
• Pentabio (pentavalent vaccine (DTP-HepB-Hib))
• bOPV Bio Farma (bivalent oral poliovirus vaccine)

Snippet

Sponsor: PT Bio Farma | Conditions: Healthy | Phase 4 | Status: COMPLETED